Literature DB >> 16900300

Tacrolimus as a reinforcement therapy for a patient with MPO-ANCA-associated diffuse alveolar hemorrhage.

Satoko Kawasaki1, Hideki Nakamura, Emi Honda, Nozomi Iwanaga, Atsushi Kawakami, Hiroaki Ida, Tomoki Origuchi, Shoko Honda, Yoshiko Tsuchihashi, Hiroyuki Yoshimine, Katsumi Eguchi.   

Abstract

A 67-year-old woman, suffering from continuous hemoptysis, was admitted to our hospital where she was managed with mechanical ventilation. Computed tomography of the chest demonstrated bilateral massive alveolar hemorrhage without evidence of infectious disease. She was diagnosed with anti-myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-associated diffuse alveolar hemorrhage because a high titer of MPO-ANCA was found in the serum. Plasmapheresis as well as methylprednisolone pulse therapy were initiated, followed by intravenous administration of cyclophosphamide. Tacrolimus was employed for the maintenance therapy, and the oral prednisolone dosage could successfully be tapered without recurrence, along with the decrement of the titer of MPO-ANCA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900300     DOI: 10.1007/s10067-006-0355-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  14 in total

1.  [Guideline for the management of ALI/ARDS].

Authors: 
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2005-10

2.  Influence of plasma exchange on serum levels of cytokines and adhesion molecules in ANCA-positive renal vasculitis.

Authors:  V Tesar; E Jelínková; Z Masek; M Jirsa; J Zabka; J Bartůnková; A Stejskalová; I Janatková; T Zima
Journal:  Blood Purif       Date:  1998       Impact factor: 2.614

Review 3.  FK-506--how much potential?

Authors:  A W Thomson
Journal:  Immunol Today       Date:  1989-01

4.  The role of computed tomography (CT) in the investigation of unexplained haemoptysis.

Authors:  A B Millar; A E Boothroyd; D Edwards; M R Hetzel
Journal:  Respir Med       Date:  1992-01       Impact factor: 3.415

Review 5.  Diffuse alveolar hemorrhage syndromes.

Authors:  U Specks
Journal:  Curr Opin Rheumatol       Date:  2001-01       Impact factor: 5.006

6.  Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha.

Authors:  Dennis Huugen; Hong Xiao; Anita van Esch; Ronald J Falk; Carine J Peutz-Kootstra; Wim A Buurman; Jan Willem Cohen Tervaert; J Charles Jennette; Peter Heeringa
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

7.  Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).

Authors:  D Lauque; J Cadranel; R Lazor; J Pourrat; P Ronco; L Guillevin; J F Cordier
Journal:  Medicine (Baltimore)       Date:  2000-07       Impact factor: 1.889

Review 8.  Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis.

Authors:  Philip J Klemmer; W Chalermskulrat; Michael S Reif; Susan L Hogan; David C Henke; Ronald J Falk
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

9.  Antineutrophil cytoplasmic antibody positive alveolar haemorrhage during propylthiouracil therapy for hyperthyroidism.

Authors:  Keiko Yamauchi; Makoto Sata; Jun-Ichi Machiya; Daisuke Osaka; Toshihiro Wada; Shuichi Abe; Kazuhisa Otake; Isao Kubota
Journal:  Respirology       Date:  2003-12       Impact factor: 6.424

10.  Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus.

Authors:  Ken-ichi Hoshi; Masayuki Matsuda; Mariko Ishikawa; Shigeaki Mitsuhashi; Takahisa Gono; Takao Hashimoto; Shu-ichi Ikeda
Journal:  Clin Rheumatol       Date:  2004-03-06       Impact factor: 2.980

View more
  1 in total

1.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.